In the lawless eastern reaches of the Democratic Republic of Congo, a different sort of frontline is taking shape. Health workers battling the latest Ebola outbreak are risking their lives not only against the virus but also against armed groups and community mistrust. Yet amid the chaos, a UK-led vaccination programme is being hailed as a humanitarian beacon. The praise is welcome, but the bottom line is this: such efforts are a drop in the ocean of global health financing, and the market for pandemic preparedness remains woefully underdeveloped.
The outbreak, centred in North Kivu province, has already claimed dozens of lives. The World Health Organisation has deployed thousands of doses of the Ervebo vaccine, developed with substantial British investment. The UK’s contribution of £10 million and logistical support has been singled out by the WHO as a model of international cooperation. But let’s not kid ourselves: this is a Band-Aid on a bullet wound. The real story is the chronic underinvestment in African health systems, a market failure that no amount of humanitarian cheerleading can fix.
Consider the economics. The cost of developing and manufacturing the Ebola vaccine was borne largely by public funds, with the UK government committing over £100 million through the UK Vaccine Network. Yet the return on that investment is measured in lives saved, not in shareholder dividends. That is fine for a charity, but it is no basis for a sustainable health security architecture. The private sector, quite rationally, sees little profit in vaccines for diseases that primarily afflict the poor. So we are left with a patchwork of donor-funded initiatives that lurch from crisis to crisis.
The situation in DR Congo is made worse by the region’s instability. Armed groups control large swathes of territory, and health workers have been attacked, kidnapped, and even killed. The vaccination teams operate under armed escort, a sobering reminder that in parts of the world, the rule of law is a foreign concept. This is not a problem that can be solved by more vaccines alone. It requires a functioning state, security, and economic opportunity. None of those are on the horizon.
The Treasury mandarins in Whitehall will no doubt pat themselves on the back for the UK’s leading role. But they should also ask why we are still playing whack-a-mole with infectious diseases. The answer lies in the failure of global health markets. For every pound spent on a vaccine, we should be spending ten on surveillance systems, local manufacturing capacity, and health worker training. That is the only way to break the cycle of panic and neglect.
Of course, the short-termism is not confined to Westminster. The bond markets are singularly unimpressed by outbreaks in distant lands. Yields on DRC sovereign debt, already in distressed territory, barely twitch at Ebola news. The market’s message is clear: these events do not matter for the global economy. But that is a dangerous delusion. A pandemic knows no borders, as we learned in 2020. The next one may be far more virulent, and we will have no one to blame but ourselves for failing to invest in the infrastructure that could have contained it.
For now, the health workers in Congo deserve our applause and our resources. They are doing a job that most of us would run from. But the applause should not distract from the underlying fiscal and market failures that make their heroism necessary in the first place. The humanitarian beacon is a noble thing, but it also illuminates the darkness of our collective neglect.
